3'-prodrugs of 2'-deoxy-beta-L-nucleosides
AssigneesIdenix Pharmaceuticals, Inc., Cnrs, L'Universite Montpellier II
InventorsJean-Louis Imbach, Martin L. Bryant, Gilles Gosselin
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds, compositions and methods for the treatment of a host infected with a hepatitis B virus. Specifically, compound and compositions of 3′-esters of 2′-deoxy-β-L-nucleosides are disclosed, which can be administered either alone or in combination with other anti-hepatitis B agents. Compound and compositions of 3′,5′-diesters of 2′-deoxy-β-L-nucleosides are disclosed, which can be administered either alone or in combination with other anti-hepatitis B agents, are also disclosed.
Claims174
A 3′-substituted-β-L nucleoside of the formula (I):
- 29
- or its pharmaceutically acceptable salt thereof, wherein
- R1 is hydrogen, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative;
- R2 is selected from the group consisting of straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative;
- X is O, S, SO2 or CH2;
- and
- BASE is a purine or pyrimidine base that may optionally be substituted.
A compound of the formula
- 38
- or its pharmaceutically acceptable salt thereof.
A compound of the formula
- 39
- or its pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising a compound of the formula
- 40
- or its pharmaceutically acceptable salt thereof, in combination with β-L-deoxyribothymidine.
A pharmaceutical composition comprising a compound of the formula
- 41
- or its pharmaceutically acceptable salt thereof, in combination with β-L-deoxyribothymidine.
A method for the treatment or prophylaxis of a hepatitis B virus infection in a host, comprising administering a therapeutic amount of a pharmaceutical composition comprising a compound of the formula
- 44
- or its pharmaceutically acceptable salt thereof, in combination or alternation with a therapeutic amount of β-L-deoxyribothymidine.
A method for the treatment or prophylaxis of a hepatitis B virus infection in a host, comprising administering a therapeutic amount of a pharmaceutical composition comprising a compound of the formula
- 45
- or its pharmaceutically acceptable salt thereof, in combination or alternation with a therapeutic amount of β-L-deoxyribothymidine.
Dependencies are inferred from the claim text.